-------------------------------------------------
E-Drug:Nimesulide (Final comment)
[Moderators Comment: Thank you Leo for this comprehensive and interesting
report. I think that we can drop this string as I suspect Nimesulide is a
drug hardly wort discussing. Richard Laing]
I did some further literature research on nimesulide. It is an old drug
with a Belgian patent dating back to 1974 (!), probably originating
from UCB, and held by then 3M-Riker. It has become somewhat of a
hand-me-down drug, successively marketed by Boehringer
Ingelheim, a small Swiss firm in the Italian part of Switzerland,
"Helsinn SA", and it is now mainly manufactured in India by a
number of firms ("Lotus International", "Dharka" etc.). It is now - as
far as I can trace - only marketed in Italy, Portugal and Switzerland
under a number of different trade names (see Martindale XXXI,
p.71). There has been some revival of interest in the drug because it
was claimed, like meloxicam, to be a preferential COX-2 inhibitor,
but, like meloxicam, proof is thin. A skeleton better left in the
cupboard? No Western European country seems very eager to
have it....
Because of the lack of proper scientific and registration data our
colleagues in India certainly have a problem.
Best wishes.
Dr.L.Offerhaus
Koedijklaan 1a, NL-1406KW Bussum, The Netherlands
Phone: +31-35-6923288. Fax: +31-35-6923290
E-mail: LO@EURONET.NL CompuServe: 71530,15
Eur J Clin Pharmacol ONLY:
POB 75552, NL-1070AN Amsterdam, The Netherlands
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.